1 Targeted Drugs for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drugs for NSCLC
1.2 Classification of Targeted Drugs for NSCLC by Types
1.2.1 Global Targeted Drugs for NSCLC Revenue Comparison by Types (2020-2025)
1.2.2 Global Targeted Drugs for NSCLC Revenue Market Share by Types in 2018
1.2.3 Target EGFR
1.2.4 Target ALK
1.2.5 Target HER2
1.2.6 Target ROS1
1.2.7 Target BRAF
1.2.8 Target MEK
1.2.9 Target VEGFR2
1.2.10 Target VEGF
1.2.11 Target MET
1.3 Global Targeted Drugs for NSCLC Market by Application
1.3.1 Global Targeted Drugs for NSCLC Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drugs for NSCLC Market by Regions
1.4.1 Global Targeted Drugs for NSCLC Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for NSCLC Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for NSCLC Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for NSCLC Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for NSCLC Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for NSCLC Status and Prospect (2015-2025)
1.5 Global Market Size of Targeted Drugs for NSCLC (2015-2025)
2 Manufacturers Profiles
2.1 Allergan
2.1.1 Business Overview
2.1.2 Targeted Drugs for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Allergan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.2 Amgen
2.2.1 Business Overview
2.2.2 Targeted Drugs for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Amgen Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.3 ARIAD Pharmaceuticals (Takeda)
2.3.1 Business Overview
2.3.2 Targeted Drugs for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.4 Beacon Pharma Limited
2.4.1 Business Overview
2.4.2 Targeted Drugs for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.5 BeiGene
2.5.1 Business Overview
2.5.2 Targeted Drugs for NSCLC Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 BeiGene Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.6 Biocon
2.6.1 Business Overview
2.6.2 Targeted Drugs for NSCLC Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Biocon Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.7 Boehringer-Ingelheim
2.7.1 Business Overview
2.7.2 Targeted Drugs for NSCLC Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.8 Celgene Corporation
2.8.1 Business Overview
2.8.2 Targeted Drugs for NSCLC Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Celgene Corporation Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.9 Drug International Limted
2.9.1 Business Overview
2.9.2 Targeted Drugs for NSCLC Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Drug International Limted Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.10 Fujifilm Kyowa Kirin Biologics
2.10.1 Business Overview
2.10.2 Targeted Drugs for NSCLC Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.11 Genvio Pharma Limited
2.11.1 Business Overview
2.11.2 Targeted Drugs for NSCLC Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.12 Hetero Drugs
2.12.1 Business Overview
2.12.2 Targeted Drugs for NSCLC Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Hetero Drugs Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.13 ImClone Systems (Eli Lilly)
2.13.1 Business Overview
2.13.2 Targeted Drugs for NSCLC Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.14 Incepta Pharmaceuticals
2.14.1 Business Overview
2.14.2 Targeted Drugs for NSCLC Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.15 Mylan
2.15.1 Business Overview
2.15.2 Targeted Drugs for NSCLC Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Mylan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.16 Novartis
2.16.1 Business Overview
2.16.2 Targeted Drugs for NSCLC Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Novartis Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.17 Pfizer
2.17.1 Business Overview
2.17.2 Targeted Drugs for NSCLC Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Pfizer Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.18 Reliance Lifesciences
2.18.1 Business Overview
2.18.2 Targeted Drugs for NSCLC Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.19 Roche
2.19.1 Business Overview
2.19.2 Targeted Drugs for NSCLC Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Roche Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.20 AstraZeneca
2.20.1 Business Overview
2.20.2 Targeted Drugs for NSCLC Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 AstraZeneca Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.21 Cipla
2.21.1 Business Overview
2.2.2 Targeted Drugs for NSCLC Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Cipla Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.22 Teva
2.22.1 Business Overview
2.22.2 Targeted Drugs for NSCLC Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Teva Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.23 OSI Pharmaceuticals
2.23.1 Business Overview
2.23.2 Targeted Drugs for NSCLC Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.24 Glenmark Pharmaceuticals
2.24.1 Business Overview
2.24.2 Targeted Drugs for NSCLC Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.25 Natco Pharma
2.25.1 Business Overview
2.25.2 Targeted Drugs for NSCLC Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Natco Pharma Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
3 Global Targeted Drugs for NSCLC Market Competition, by Players
3.1 Global Targeted Drugs for NSCLC Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drugs for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drugs for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drugs for NSCLC Market Size by Regions
4.1 Global Targeted Drugs for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
4.3 Europe Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
4.5 South America Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
5 North America Targeted Drugs for NSCLC Revenue by Countries
5.1 North America Targeted Drugs for NSCLC Revenue by Countries (2015-2019)
5.2 USA Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
5.3 Canada Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
5.4 Mexico Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
6 Europe Targeted Drugs for NSCLC Revenue by Countries
6.1 Europe Targeted Drugs for NSCLC Revenue by Countries (2015-2019)
6.2 Germany Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
6.3 UK Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
6.4 France Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
6.5 Russia Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
6.6 Italy Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Targeted Drugs for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drugs for NSCLC Revenue by Countries (2015-2019)
7.2 China Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
7.3 Japan Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
7.4 Korea Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
7.5 India Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
8 South America Targeted Drugs for NSCLC Revenue by Countries
8.1 South America Targeted Drugs for NSCLC Revenue by Countries (2015-2019)
8.2 Brazil Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
8.3 Argentina Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
8.4 Colombia Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Targeted Drugs for NSCLC by Countries
9.1 Middle East and Africa Targeted Drugs for NSCLC Revenue by Countries (2015-2019)
9.2 Saudi Arabia Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
9.3 UAE Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
9.4 Egypt Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
9.5 Nigeria Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
9.6 South Africa Targeted Drugs for NSCLC Revenue and Growth Rate (2015-2019)
10 Global Targeted Drugs for NSCLC Market Segment by Type
10.1 Global Targeted Drugs for NSCLC Revenue and Market Share by Type (2015-2019)
10.2 Global Targeted Drugs for NSCLC Market Forecast by Type (2020-2025)
10.3 Target EGFR Revenue Growth Rate (2015-2025)
10.4 Target ALK Revenue Growth Rate (2015-2025)
10.5 Target HER2 Revenue Growth Rate (2015-2025)
10.6 Target ROS1 Revenue Growth Rate (2015-2025)
10.7 Target BRAF Revenue Growth Rate (2015-2025)
10.8 Target MEK Revenue Growth Rate (2015-2025)
10.9 Target VEGFR2 Revenue Growth Rate (2015-2025)
10.10 Target VEGF Revenue Growth Rate (2015-2025)
10.11 Target MET Revenue Growth Rate (2015-2025)
11 Global Targeted Drugs for NSCLC Market Segment by Application
11.1 Global Targeted Drugs for NSCLC Revenue Market Share by Application (2015-2019)
11.2 Targeted Drugs for NSCLC Market Forecast by Application (2020-2025)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2015-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
12 Global Targeted Drugs for NSCLC Market Size Forecast (2020-2025)
12.1 Global Targeted Drugs for NSCLC Market Size Forecast (2020-2025)
12.2 Global Targeted Drugs for NSCLC Market Forecast by Regions (2020-2025)
12.3 North America Targeted Drugs for NSCLC Revenue Market Forecast (2020-2025)
12.4 Europe Targeted Drugs for NSCLC Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Targeted Drugs for NSCLC Revenue Market Forecast (2020-2025)
12.6 South America Targeted Drugs for NSCLC Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Targeted Drugs for NSCLC Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
